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Introduction
Angiotensin II (ANG II) is known to be a potent growth promoting factor for vascular smooth muscle cells and fibroblasts but little is known about its influence on growth in endothelial cells. We studied the effects of ANG II on endothelial growth and the role of the angiotensin receptor subtypes involved. Proliferation of rat coronary endothelial cells (CEC) and rat vascular smooth muscle cells (VSMC) was determined by [3H] thymidine incorporation, the MTTtest and by directly counting cells in a coulter counter. Angiotensin AT1and AT2-receptors were demonstrated by binding studies and by the presence of their respective mRNA through reverse transcription polymerase chain reaction (RT-PCR).
In contrast to VSMC, which in culture only express the AT1-receptor, CEC express both, AT1and AT2-receptors simultaneously up to the third passage. Whereas ANG II stimulated growth of quiescent VSMC, an effect abolished by pretreatment with the ATl-receptor antagonist, losartan, ANG II did not induce proliferation in quiescent CEC. However, after pretreatment of quiescent endothelial cells (< passage 4) with the AT2-receptor antagonist, PD 123177, ANG II induced proliferation. This effect was reversed by additional pretreatment with losartan. ANG II significantly inhibited the proliferation of bFGF-stimulated CEC in a dose-dependent manner by maximally 50%. This effect was prevented by PD 123177 while losartan was ineffective. The AT2-receptor agonist, CGP 42112, mimicked the antiproliferative actions of ANG II, confirming the specificity of the effect.
Our results show that the growth modulating actions of ANG II depend on the type of angiotensin receptor present on a given cell. In coronary endothelial cells, the antiproliferative actions of the AT2-receptor offset the growth promoting effects mediated by the AT1-receptor. (J. Clin. Invest. 1995 . 95:651-657.) Key words: angiotensin receptors * bFGF * endothelial cells * PD 123177 * CGP 42112 * Losartan * RT-PCR Angiotensin II (ANG II),' the main effector peptide of the renin-angiotensin system, has long been known to play an important role in the regulation of blood pressure and body fluid homeostasis. More recently, ANG II has been reported to induce hyperplasia or hypertrophy in cultured vascular smooth muscle cells derived from the aorta (1) (2) (3) (4) , in small resistance arteries (5) and in cardiomyocytes (6) .
We have previously observed that chronic oral treatment of spontaneously hypertensive rats (SHR) with an angiotensin converting enzyme inhibitor induced myocardial capillary growth independently of the antihypertensive and antihypertrophic actions of the drug (7) . Theoretically, this effect could be due to a potentiation of endogenous kinins or to a reduced generation of ANG II. In the latter case, one would have to expect an antiproliferative effect of ANG II on myocardial endothelial cells which gives rise to cardiac capillaries. This hypothesis is at variance with the widely accepted idea of ANG II being a growth promoting factor in cardiovascular tissues. However, using coronary endothelial cells (CEC) from SHR and normotensive Wistar Kyoto rats in primary culture, we recently found that ANG II significantly attenuated proliferation when growth was stimulated by fetal calf serum (8, 9) . Thus, in contrast to its proliferating effects on vascular smooth muscle cells (VSMC), ANG II may indeed exert antiproliferative actions on vascular endothelial cells.
VSMC in culture, a common cell line to study the trophic effects of ANG II, exclusively express ATIand no AT2-receptors (10). Therefore, ANG 11-induced growth shown in VSMC in vitro has been attributed to the ATl-receptor. The obvious discrepancy between the effects of ANG II on VSMC and on microvascular endothelial cells could be explained twofold. First, angiotensin receptors on endothelial cells could be identical to those on VSMC (i.e., ATI) but coupled to intracellular pathways different from those present in VSMC. Second, the antiproliferative response to treatment with ANG II, as observed in endothelial cells, could be due to the stimulation of an angiotensin receptor subtype different from AT1, for instance the AT2-receptor. In addition, the antiproliferative effect of ANG II could be a phenomenon occurring in serum-stimulated rat cardiac microvascular endothelial cells but not a general feature of CEC under stimulation with defined growth factors.
In the present study we investigated, first, whether ANG II is antimitogenic for CEC stimulated to proliferate by the administration of a defined growth factor and second, by which angiotensin receptor subtype, ATl or AT2, the antimitogenic effect of ANG II is mediated. Using different test systems, [3H]thymidine incorporation, the MTT proliferation assay and cell counts, we demonstrate that ANG II significantly inhibits growth in bFGF-stimulated coronary endothelial cells and that this effect is mediated by the AT2-receptor. Our results suggest that the presence of the respective angiotensin receptor subtypes, AT1 and AT2, on a given cell determines whether the peptide exerts proliferative or antiproliferative actions.
Methods
Cell culture. VSMC were isolated from rat aortae by enzymatic digestion as previously described (3) . VSMC were cultured in medium containing a 1:1 formulation of DME and HAM's F12 medium, supplemented with 10% FCS, L-glutamine ( 1 mM), penicillin ( 100 U/ml) and streptomycin (100 jg/ml). Cells were harvested for passaging at subconfluence with a trypsin-EDTA (0.25% trypsin and 0.02% EDTA) solution. VSMC identity and the purity of cultures were verified by immunohistochemical analysis using a monoclonal antibody for smooth muscle a-actin.
Rat CEC were isolated as described by Piper et al. ( 11) . In brief, hearts from anesthetized and heparinized (intraperitoneal injection of 60 mg/ml per kg sodium pentobarbital and 5,000 I.U. sodium heparin) male SHR weighing 180-250 g were excised and mounted via the aorta to a Langendorff perfusion system. Nonrecirculating perfusion was started immediately at a flow rate of 10 ml/min with a modified Krebs-Henseleit solution containing 110 mM NaCl, 2.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM NaHCO3, 11 mM glucose and gassed with carbogen (95% 02, 5% C02). After 5 min, perfusion was switched to recirculating mode with Krebs-Henseleit solution supplemented with 136 U/ ml Collagenase (Worthington CLS II), 25 U/ml Dispase (grade I) and 5 U/ml trypsin. After 30 min of perfusion, atria were discarded, the ventricles minced and again incubated in protease solution. The cell homogenate was filtered through a nylon mesh (200 ,um) and centrifuged at 25 g for 3 min. The supernatant was further dissociated for 30 min with protease solution containing 4% bovine serum albumine (BSA) and trypsin (5 U/ml). Cells were seeded on collagen A (containing 975% collagen type I and 3% type IV)-precoated dishes and cultured in DME supplemented with 20% FCS, 50 jig/ml endothelial cell growth supplement and 50 jg/ml heparin.
Cells were harvested for passaging at subconfluence with a trypsin-EDTA (0.05% trypsin and 0.02% EDTA) solution. Endothelial cells were characterized by their cobblestone morphology and the presence of the receptor for acetylated LDL (12) . Purity of culture was verified by the lack of staining with a monoclonal antibody for smooth muscle a-actin to exclude pericyte contamination.
Cell cultures were incubated at 37°C in a humified atmosphere of 5% C02-95% air. VSMC were used from passages 10-28, CEC were used exclusively up to the third passage.
[3H] Thymidine incorporation. . Cells were then fixed in fixative for 20 min at 37°C and for 10 min with 0.3 M perchloric acid, followed by a thorough rinse with distilled water. The fixed cells were incubated for 20 min in 100 til of a 0.25 M NaOH before an equal volume of distilled water was added. The hydrolysate was than transferred to scintillation vials with 3 ml of scintillation fluid, and samples were counted for 5 min in a beta-counter. Proliferation assay. Cell proliferation was measured using the Cell-Titer 96T' Cell Proliferation Assay (Promega, Merdeson, WI), which uses cellular conversion of a tetrazolium salt into a blue formazan product (MTT-test) ( 14) . Absorbance was measured in an ELISA-reader at 570 and 620 nm (for reference) and was used as a parameter for cell number. Additionally, cell number was directly determined using a Coulter particle counter as described previously (15) with slight modifications.
Experimental protocol. For [3H] thymidine incorporation and MTTtest cells were seeded subconfluently on collagen A-precoated 96multiwell plates and for determination of cell number by cell count on 24-multiwell plates. Quiescence was achieved by serum deprivation in standard culture medium supplemented with 1% FCS for at least 48 h.
The following experiments were then performed. Treatment of quiescent cells with ANG II (10-' to 10-6 M, n = 10), with ANG II (10-7 M) after pretreatment with the respective ATland AT2-receptor antagonists, losartan and PD 123177 (10-7 to 10-5 M, n = 8), and the AT2agonist, CGP 42112 (1O-8 to 10-6 M), or with the angiotensin receptor ligands plus vehicle as controls (n = 8).
[3H]Thymidine incorporation and proliferation, respectively, were measured 40 to 48 h later as described above. In a second set of experiments, proliferation of quiescent cells was induced by the addition of 25 ng/ml bFGF for 24 h followed by drug treatment of the cells as above.
[3H] Thymidine incorporation and proliferation were determined 24 h later (n = 10 for each group).
Angiotensin receptor binding studies. Cells at their second passage were serum deprived for 48 h, harvested with trypsin/EDTA and immediately washed three times with ice-cold PBS. Membrane particulate was prepared according to a previously described method (16) . Briefly, harvested cells were homogenized in ice-cold buffer (20 mM Tris, pH 7.4, 1 mM EDTA, 0.1% BSA, 2 mM benzamidin and 0.01% bacitracin) with a Dounce homogenizer. Homogenates were centrifuged twice at 1,000 g for 10 min and the supernatants at 30,000 g for 45 min. The resulting pellet was resuspended in 20 mM Tris, pH 7.6, 1 mM EDTA at a concentration of 2 mg/ml and snap-frozen in liquid nitrogen. Protein content was determined using the Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL) with bovine serum albumin (BSA) as standard.
For competition binding experiments, membrane particulate was incubated in 200 utl binding buffer (50 mM Tris, pH 7.4, 125 mM NaCl, 6 .5 mM MgCl2, 1 mM EDTA, 0.2% BSA, 1 mM benzamidin, 0.01% bacitracin and antipain, phosphoramidon, pepstatin A, bestatin, leupeptin and amastatin (all at 1 jig/ml) at a final concentration of 350 jsg/ ml for 90 min at 25°C in the presence of ['"I]Sar'lle8ANG II (0.25 nM) as a tracer and of losartan or CGP 42112 as respectively selective ATI and AT2 competitors. The reaction was stopped with 3 ml of icecold PBS, and bound ligand was separated from free by filtration through glass-fiber filters (Whatman GF/F, Clifton, NJ) coated with 1% BSA.
Nonspecific binding was determined in the presence of 1 /AM ANG II and was less than 10% of total binding. Specific binding was calculated by subtracting non-specific from total binding. Degradation of [ 'I] Sar-'Ile8 ANG H as measured by thin-layer chromatography was < 5%. Data are the mean of three experiments analyzed with the EBDA-LIGAND programme (17) . PCR analysis of ATI and AT72 expression. The mRNA expression of the ATI and AT2 sequences was measured using RT-PCR assays. The total RNA was extracted based on the protocol of Chirgwin et al. (18) . After first-strand synthesis of RNA using random hexamers as described (19) cDNA was amplified using specific primers. For amplification of ATI, the antisense primer was GCCCTGTCCACAATA-TCTGC (extending from base 1108 through base 1127) and the sense primer TGTAAGATTGCTTICAGCCAGC (extending from base 581 through base 601) was used. For amplification of AT2, the antisense primer was ACCACTGAGCATATTTCTCGGG (base 682 through base 703) and the sense primer TGAGTCCGCATTTAACTGC (base 227 through base 245). The amplification protocol followed the procedure originally described by Paul et al. (19) . After amplification, sequences were blotted onto nylon membranes hybridized to full length cDNA probes of ATI and AT2, respectively, as described (19) . The radioactive signals were then analyzed using a computer based imaging system (Fuji BAS 2000). Reagents 
Results
Effects of ANG II on [3H] thymidine uptake and proliferation. ANG II was tested for its ability to stimulate the proliferation of quiescent microvascular CEC and aortic VSMC or to influence the mitogenic activity of proliferating CEC after stimulation with 25 ng/ml bFGF.
Application of ANG II ( 10-10 to 10-6 M) to quiescent CEC did not exert any significant actions on [3H] thymidine uptake or cell number (MTf-test: extinction 0.113+0.022 for vehicletreated CEC vs. 0.111±0.025 for ANG II (10-7 M) -treated CEC). Fig. 1 b shows the respective data for [3H]thymidine incorporation with an ANG II concentration of 0 -7 M. In contrast, a significant increase in [3H]thymidine incorporation could be observed after treatment of quiescent VSMC with ANG H at higher concentrations ( 10-7 to -10-6 M) ( Fig. 1 a) , while cell number was not influenced (MTT-test: extinction 0.211±0.010 for vehicle-treated VSMC versus 0.200±0.003 for ANG 11-treated VSMC). The ANG II-induced increase in [3H]thymidine uptake in VSMC was prevented by the specific ATIreceptor antagonist, losartan, but was not influenced by the specific AT2-receptor antagonist, PD 123177 ( Fig. 1 a) . In quiescent CEC, losartan pretreatment slightly reduced [3H]thymidine uptake after ANG 11 (Fig. 1 b) while having no effect when given alone (data not shown). In contrast, when quiescent CEC were pretreated with PD 123177, [3H]thymidine uptake was induced by ANG II (Fig. 1 b) . This effect was abolished when cells were pretreated with losartan in addition to PD 123177 ( Fig. 1 b) . Comparable results were obtained when cell number was directly determined by a Coulter particle counter (Table I) .
Treatment of CEC with ANG II (10-9 to 10-6 M) 24 h after stimulation with 25 ng/ml bFGF led to a dose-dependent decrease in [3H]thymidin uptake compared with vehicle-treated cells. This antimitogenic effect of ANG H was maximal at a concentration of 10-6 M, when proliferation of CEC was inhibited by more than 50% (Fig. 2, a and b ) compared with vehicletreated controls. The decrease in [3H]thymidine incorporation was accompanied by a similar decrease in conversion of MIT and cell number (Table I) To characterize the angiotensin receptor subtype involved in the antimitogenic action of ANG II, we examined the influ- The antimitogenic actions of ANG II on bFGF-stimulated CEC were not influenced by losartan. In contrast, pretreatment of the cells with PD 123177 totally prevented the ANG IIinduced antiproliferation (Fig. 2, b and c and Table I ). Neither of the two angiotensin receptor antagonists had an intrinsic effect on proliferating CEC (data not shown).
The AT2 agonist, CGP 42112, was found to mimic the antiproliferative effect of ANG I, but only at significantly higher concentrations (10-6 M). At lower concentrations, this compound competed for this effect of ANG II (Fig. 3 ).
Angiotensin receptor subtypes expressed by CEC and VSMC. VSMC in culture have been shown previously to express only ATI receptors (10, 21, 25) . The subtypes of ANG II receptors expressed by CEC in culture at early passages (-s 3) were identified by radioligand binding experiments using the nonselective ANG II antagonist, [125] Sar'Ile8 ANG II, as a Antimitogenic Effect of the Angiotensin A72-Receptor 653 3). The competition binding experiments performed with losartan and CGP 42112 yielded complex curves suggesting the presence of two classes of binding sites (Fig. 4 ). Computerassisted analysis of the data (after subtraction of nonspecific binding) using a non linear curve fitting programm (17) with the previously reported affinities of these compounds for ATI and AT2 receptors in other tissues and cultured cells (10, 16, 26, 28, 34, 35, 36) , thus indicating the expression of both receptor subtypes in culture. The ratio of ATi/AT2 receptors was calculated to be 80%/20%±5%.
Analysis of ATJand Af2-receptor mRNA expression in CEC. Specific mRNA transcripts for both ANG 11 receptor subtypes, ATI and AT2, could be detected in CEC up to the third cell passage by PCR analysis. All PCR products were found to be of the predicted size on agarose gels. The specificity of the PCR reaction was tested by restriction enzyme analysis of amplified products which resulted in fragments of correct size (data not shown) as well as by hybridization of the PCR products to full length cDNA probes of ATI and AT2 (Fig. 5 ).
Discussion
In preliminary studies we have reported that ANG 11 can inhibit the proliferation of coronary endothelial cells in vitro (8, 9) . The present study confirms and extends our previous findings by demonstrating that distinct growth modulating actions of ANG 11 are coupled to different angiotensin receptor subtypes.
Several investigators have shown that ANG II is a growth promoting factor for VSMC ( 1-5, 20, 21 ) and that this effect is mediated by the ATi-receptor (22) . The results of the present study using VSMC isolated from the rat aorta confirm the findings of Geisterfer et al. (3) and Berk et al. (22) . ANG II treatment engendered hypertrophy but not hyperplasia in aortic VSMC, since ANG II induced the synthesis of DNA (as reflected by the uptake of [3H] thymidine) but did not lead to an increased cell number. Thus far, an ANG 11-induced hyperplasia has only been reported for aortic VSMC originating from SHR or for VSMC isolated from mesenteric arteries (4, 5, 24) .
The growth responses of VSMC to ANG II vary depending on the target VSMC, and the mechanisms leading to differential growth responses are still controversial. Dzau et al. (25) proposed that ANG II represents a bifunctional growth factor for VSMC by simultaneously stimulating proliferative and antiproliferative pathways that appear to be mediated by the activation of platelet-derived growth factor (PDGF)-AA and transforming growth factor (TGF-f31) They reported that the mitogenic effect of ANG II was offset by the concomitant activation of TGF-,f1 which prevented proliferation. On the other hand, Stouffer and Owens (24) claimed that the ANG 11-induced mitogenesis in VSMC derived from SHR was dependent on an autocrine production of TGF-613, potentiating the mitogenic properties of ANG II in the presence of epidermal growth factor (EGF) or PDGF-BB. The discrepancies between these studies concerning the responses of VSMC to ANG 11 could be due to the experimental conditions, e.g., the presence or absence of distinct growth factors such as EGF, PDGF, bFGF, or serum. VSMC in culture express only ATIbut no AT2-receptors (10, 16, 20, 26) . Thus, the trophic effects of ANG 11 causing hyperplasia or hypertrophy can only be ascribed to the AT1receptor. Accordingly, in our study, the ATi-receptor antagonist, losartan, blocked the hypertrophic actions of ANG 11 in VSMC while the AT2-receptor antagonist, PD 123177, was ineffective. In contrast to VSMC, ANG II given alone exerted no growth promoting actions in quiescent endothelial cells. Interestingly, treatment of quiescent CEC with losartan in combination with ANG II reduced 3H-thymidine uptake below basal levels of vehicle-treated, serum-deprived cells while losartan by itself had no effect. Since vehicle-treated cells revealed a [3H]thymidine uptake of about 10.000 counts per minute, it is conceivable that complete quiescence of the cells was not achieved by partial serum deprivation with DME + 1% FCS. Therefore, this effect could be explained by the stimulation of AT2-receptors which were unmasked by blockade of the AT1receptors.
When quiescent CEC were pretreated with the AT2-receptor antagonist, PD 123177, a mitogenic action of ANG II could also be demonstrated in endothelial cells. Pretreatment with losartan in addition to PD 123177 abolished this effect. The endothelial cells used in this study express the AT1as well as the AT2-receptor. Thus, the AT2-receptor blockade obviously unmasked the growth-promoting effect of the ATI-receptor in quiescent endothelial cells. Together, these findings in quiescent VSMC and CEC suggest that ANG II can only exert a mitogenic action through the ATI-receptor when the AT2-receptor is either absent (as in cultured VSMC) or inactivated (as observed after pretreatment with PD 123177 in CEC). ANG II significantly inhibited growth of bFGF-stimulated proliferating endothelial cells in both assay systems used. Pretreatment of CEC with the AT2-antagonist, PD 123177, but not with the ATL-antagonist, losartan, prevented the ANG IIinduced endothelial antiproliferation indicating that this effect is mediated by the AT2-receptor subtype.
These findings are corrobated by the observations concerning the effect of the AT2 selective analog, CGP 42112. Whereas the antagonistic properties observed at low concentrations may appear to be in contradiction with its agonistic properties at higher concentrations, these data are in agreement with its partial agonistic properties reported recently in other systems (27- 30). Since this compound has the same affinity as ANG II for the AT2 receptor, but a lower intrinsic activity, it will compete with ANG II and inhibit its effect to a certain extent. At higher concentrations, the intrinsic activity appears to be sufficient to achieve the same final response as ANG II. The question remains, as to how AT2-receptor stimulation can exert an antimitogenic action on proliferating endothelial cells in the presence of the ATI-receptor. It is conceivable that the growth-promoting ATI effect of ANG II is inoperative in cells stimulated to proliferation by a potent growth factor such as bFGF. On the other hand, it is also possible that the AT2mediated antimitogenic effect dominates by a yet unknown mechanism over the growth-promoting actions of the ATI-receptor. Our present findings are in apparent contrast to previous observations that ANG II has angiogenic properties in vivo (31, 32) . Fernandez et al. (31) reported that ANG II, when implanted in the rabbit cornea, induced formation of new vessels. However, since the distribution of angiotensin receptors in the rabbit cornea may differ from that in CEC, the angiogenic effect of ANG II may be explained by stimulation of ATi-receptors in the absence of the AT2-receptor. Recently, Le Noble et al. (32) reported that ANG II induced angiogenesis in the chick chorioallantoic membrane. They postulated an involvement of a novel ANG II receptor subtype or the AT2-receptor in this effect. In their study, the AT2-ligand, CGP 42112, at a concentration of 2 x 10-6 M blocked the ANG II-induced angiogenesis while losartan as well as the nonpeptidergic AT2-antagonist, PD 123319, failed to significantly inhibit the angiogenic effect of ANG II. The observed effect of ANG II and its inhibition by CGP 42112 could be specific for the chick chorioallantoic membrane, since avian (33) and amphibian (34) ANG II receptors have been shown to differ from those in mammalian tissues. On the other hand, since a concentration of 2 X 10-6 M of CGP 42112A is agonistic for the AT2-receptor (see references cited above and this study) as well as antagonistic for the AT1receptor (28) , the inhibition of ANG II-induced angiogenesis in the chick chorioallantoic membrane by this compound is difficult to interpret.
Little is known as of this writing on the function of the AT2-receptor. Although the AT2-receptor has recently been cloned (35, 36) its structure and signal transduction pathway are still far from being completely understood. The rat AT2receptor cDNA encodes for a 363-amino acid protein that has a seven transmembrane domain topology and a homology of 32-34% in its amino acid sequence to the ATI-receptor. However, it is still controversial whether it is coupled to G-proteins, and how it signals. Kambayashi et al. (35) reported that the rat AT2-receptor (expression cloned from a rat pheochromocytoma cell line) mediates an inhibition of a phosphotyrosine phosphatase in COS-7-cells (stably expressing the rat AT2-receptor). This effect is dependent on a pertussis toxin-sensitive, G-protein coupled mechanism. On the other hand, Mukoyama et al. (36) reported that the rat AT2-receptor shares a seven transmembrane domain topology which may belong to a unique class of seven transmembrane receptors for which G-protein coupling has not been demonstrated. In their studies, stimulation of the cloned AT2-receptor (transiently expressed in COS-7-cells) failed to increase 1P3 or intracellular calcium, and no apparent effects on cAMP and cGMP levels and phosphotyrosine phosphatase activity could be observed. The authors speculated that a highly conserved motif in the third intracellular loop distinguishes this class of receptors from the classical G-proteincoupled receptors.
In NG 108-15 cells, which constitutively express AT2 receptors, Buisson et al. (37) have shown that AT2 receptor stimulation results in the inhibition of T-type calcium channels through an as yet undefined pathway. In another cell line, which also only expresses AT2 receptors, Bottari and collegues reported that ANG H stimulates a membrane associated phosphotyrosine phosphatase (PTP) activity (29) and inhibits ANP-sensitive particulate guanylate cyclase (30, 38) . Both effects are G-Protein independent ( 16, 29) , and the inhibition of particulate guanylate cyclase is abolished by blockade of PTP activity, thus suggesting that both responses are linked and that PTP activation occurs upstream from particulate guanylate cyclase inhibition (30) . The PTP involved appears to have several substrates which, however, still have to be further characterized (29) .
These findings are compatible with our data since it has been shown that sodium orthovanadate, an inhibitor of phosphotyrosine phosphatases, may induce angiogenesis in vivo (39) . It is conceivable that after stimulation of a phosphotyrosine phosphatase the opposite, i.e., a decreased proliferation, may occur. This may be particularly pertinent with regard to the inhibition of the mitogenic effect of bFGF which is known to involve multiple tyrosine phosphorilations.
Results from binding studies have demonstrated that the appearance of AT2-receptors is subjected to significant changes during development and differentiation. For instance, in rats the proportion of ATIand AT2-receptors in most tissues changes dramatically during the postnatal period (40, 41) . While in fetal tissues AT2-receptors are by far dominating, in adult animals it is the AT1-receptor. In addition, an increased expression of AT2-receptors has been described in pathophysiological conditions such as vascular neointima proliferation (42) or left ventricular hypertrophy due to aortic banding (43) .
The observation of transient expression of the AT2-receptor during development together with that of an AT2-induced stimulation of phosphotyrosine phosphatase activity suggest that this receptor subtype is involved in the control of cell proliferation and differentiation. In view of the above mentioned and our present findings, one could speculate that a major function of the AT2-receptor is to tune down excessive proliferative actions of growth factors including those of ANG II via the ATi-receptor. This growth modulatory action of the AT2-receptor may be of particular importance during development or in pathophysiological situations involving remodelling and tissue repair.
